Company Details

Actinogen Medical Ltd (ASX: ACW)

ASX Listed
ASX Listed, Research and Development
Healthcare / Life Sciences / Medical Devices
General Investor Profiling

Company Information

  • Executive Summary

    Executive Summary

    Actinogen Medical Limited (ASX:ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease. Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting activity of the human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), which catalyses the conversion of cortisone to cortisol. Chronic, high levels of cortisol, the “stress hormone” is associated with cognitive decline, the development of beta-amyloid plaques and hippocampal atrophy- which are the hallmarks of Alzheimer’s disease. 11βHSD1 enzyme is highly expressed through-out the brain, including the hippocampus and frontal cortex which are important regions for cognition; these regions also show high expression of glucocorticoid receptors which mediate the effects of cortisol. Reducing cortisol action in the CNS has therefore emerged as an important therapeutic goal in the treatment of Alzheimer’s disease. Xanamem™ was optimised to be highly CNS penetrant to block the production of cortisol in the brain by direct inhibition of the 11βHSD1 enzyme.

    Actinogen successfully completed the necessary preclinical and human safety and pharmacokinetic studies to confirm that Xanamem™ is well tolerated with an acceptable safety profile. In addition, analysis of corticospinal fluid from pharmacokinetic studies in health volunteers demonstrated that Xanamem™ can cross the blood-brain-barrier at concentrations predicted to be adequate to inhibit the 11bHSD1 enzyme. Actinogen is well advanced with plans to initiate a Phase II efficacy and safety study in mild Alzheimer’s disease patients in the second quarter of 2016. This clinical trial will be conducted in Australia, the United Kingdom and the United States, under an FDA approved IND.

    • Xanamem™ represents an innovative, differentiated mechanism of action targeting
      the stress hormone cortisol.
    • Xanamem™ is an oral medication designed to penetrate the brain, and mediate action at low doses.
    • Xanamem™ was found to be safe and well tolerated in healthy human subjects.
    • Actinogen is supported by a world-renowned Clinical and Scientific Advisory Board.
  • Company Highlights

    Company Highlights

    • ACW’s lead product Xanamem’s™ is targeting Alzheimer’s disease- a significant unmet need in a huge and growing global market.
    • Xanamem’s™ represents an innovative, differentiated mechanism of action targeting
      the stress hormone cortisol.
    • There is some evidence that Xanamem™ is both symptomatic and disease modifying.
    • A Phase II XanADu study is fully funded through to completion.
    • Xanamem’s™ is backed with patent protection through to 2031 – covering composition of matter.
    • ACW is pursuing value-enhancing additional indications in substantive markets
      of interest to big pharmaceutical companies.
  • Board & Management

    Board & Management

    Dr. Bill Ketelbey

    CEO & Managing Director
    • MD with 30 years’ experience in pharmaceuticals. • Senior roles at Pfizer, including development of Aricept™, the current leading AD treatment.

    Martin Rogers

    Executive Chairman
    • Biotechnology entrepreneur and executive, with financial market capital raising experience, having raised over $100 M cash equity. • Non-Executive Director of Oncosil Medical (ASX:OSL).

    Dr. Jason Loveridge

    Non-Executive Director
    • Over 20 years’ experience in developing clinical stage biotechnology companies. • Director JAFCO Nomura London. • Participated in over 29 biotech investments in the EU, US and Israel. • Non-Executive Director of Resonance Health...

    Dr. Anton Uvarov

    Non-Executive Director
    • Healthcare and biotech equities analyst, formerly Citibank NY. • Non-Executive Director Imugene (ASX: IMU).

    Peter Webse

    Company Secretary
    • 23 years of company secretarial experience • Managing director of Platinum Corporate Secretariat, and Non-Executive Director of Cynata.

    Vincent Ruffles

    Vice President of Clinical Research
    • Extensive drug development experience over 20 years. • Responsible clinical development and regulatory strategy.
  • Company News
  • Contact Details

    Contact Details